{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T18:24:45Z","timestamp":1791915885385,"version":"4.3.4"},"reference-count":42,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:00:00Z","timestamp":1763424000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016879","name":"UCB SA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016879","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011110","name":"UCB","doi-asserted-by":"publisher","award":["GPP 2022"],"award-info":[{"award-number":["GPP 2022"]}],"id":[{"id":"10.13039\/100011110","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.jaad.2025.11.031","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T07:51:54Z","timestamp":1763625114000},"page":"867-878","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Bimekizumab demonstrated a favorable safety profile and high levels of efficacy with up to 2 years of treatment in patients with moderate to severe hidradenitis suppurativa: Pooled results from two phase 3 randomized, controlled trials and their open-label extension"],"prefix":"10.1016","volume":"94","author":[{"given":"Christopher J.","family":"Sayed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Kirby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Garg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haley B.","family":"Naik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexa B.","family":"Kimball","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos C.","family":"Zouboulis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregor B.E.","family":"Jemec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgios","family":"Kokolakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John R.","family":"Ingram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akimichi","family":"Morita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine","family":"Deherder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Crater","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert L.","family":"Rolleri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Vaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00e9my","family":"Lambert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bartosz","family":"Lukowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Falk G.","family":"Bechara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.jaad.2025.11.031_bib1","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.3390\/cells10082094","article-title":"Hidradenitis suppurativa: where we are and where we are going","volume":"10","author":"Scala","year":"2021","journal-title":"Cells"},{"issue":"6","key":"10.1016\/j.jaad.2025.11.031_bib2","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1111\/bjd.19556","article-title":"Aetiology and pathogenesis of hidradenitis suppurativa","volume":"183","author":"Wolk","year":"2020","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2025.11.031_bib3","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1159\/000431175","article-title":"Hidradenitis suppurativa\/Acne inversa: criteria for diagnosis, severity assessment, classification and disease evaluation","volume":"231","author":"Zouboulis","year":"2015","journal-title":"Dermatology"},{"issue":"1","key":"10.1016\/j.jaad.2025.11.031_bib4","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/jdv.16677","article-title":"Hidradenitis suppurativa: an update on epidemiology, phenotypes, diagnosis, pathogenesis, comorbidities and quality of life","volume":"35","author":"Nguyen","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"10.1016\/j.jaad.2025.11.031_bib5","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.jaci.2023.05.012","article-title":"Single-cell transcriptomics suggest distinct upstream drivers of IL-17A\/F in hidradenitis versus psoriasis","volume":"152","author":"Kim","year":"2023","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.jaad.2025.11.031_bib6","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/cei.13449","article-title":"IL-17 in inflammatory skin diseases psoriasis and hidradenitis suppurativa","volume":"201","author":"Fletcher","year":"2020","journal-title":"Clin Exp Immunol"},{"issue":"10","key":"10.1016\/j.jaad.2025.11.031_bib7","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.3390\/biom12101371","article-title":"Transcriptome meta-analysis confirms the hidradenitis suppurativa pathogenic triad: upregulated inflammation, altered epithelial organization, and dysregulated metabolic signaling","volume":"12","author":"de Oliveira","year":"2022","journal-title":"Biomolecules"},{"issue":"4","key":"10.1016\/j.jaad.2025.11.031_bib8","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.jaad.2024.11.050","article-title":"A genome-wide association meta-analysis links hidradenitis suppurativa to common and rare sequence variants causing disruption of the Notch and Wnt\/\u03b2-catenin signaling pathways","volume":"92","author":"Kj\u00e6rsgaard Andersen","year":"2025","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2025.11.031_bib9","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1159\/000533739","article-title":"High unemployment rate in patients with hidradenitis suppurativa despite high educational attainment","volume":"240","author":"Kearney","year":"2024","journal-title":"Dermatology"},{"issue":"13","key":"10.1016\/j.jaad.2025.11.031_bib10","doi-asserted-by":"crossref","first-page":"821","DOI":"10.21037\/atm-20-1028","article-title":"Hidradenitis suppurativa and psychiatric comorbidities, suicides and substance abuse: systematic review and meta-analysis","volume":"8","author":"Phan","year":"2020","journal-title":"Ann Transl Med"},{"issue":"8","key":"10.1016\/j.jaad.2025.11.031_bib11","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1111\/jdv.20607","article-title":"Cumulative life course impairment: evidence for hidradenitis suppurativa","volume":"39","author":"Doroudian Tehrani","year":"2025","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"7","key":"10.1016\/j.jaad.2025.11.031_bib12","doi-asserted-by":"crossref","first-page":"6596","DOI":"10.3390\/ijms24076596","article-title":"Screening for diabetes mellitus in patients with hidradenitis suppurativa: a monocentric study in Germany","volume":"24","author":"Abu Rached","year":"2023","journal-title":"Inter J Mol Sci"},{"issue":"4","key":"10.1016\/j.jaad.2025.11.031_bib13","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.jaad.2023.12.030","article-title":"Population-based mortality in hidradenitis suppurativa: a systematic review","volume":"90","author":"Mohsen","year":"2024","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2025.11.031_bib14","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.jaad.2021.01.059","article-title":"Comorbidity screening in hidradenitis suppurativa: evidence-Based recommendations from the US and Canadian hidradenitis suppurativa foundations","volume":"86","author":"Garg","year":"2022","journal-title":"J Am Acad Dermatol"},{"issue":"10476","key":"10.1016\/j.jaad.2025.11.031_bib15","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/S0140-6736(24)02475-9","article-title":"Hidradenitis suppurativa","volume":"405","author":"Sabat","year":"2025","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.jaad.2025.11.031_bib16","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1111\/jdv.20550","article-title":"Hidradenitis suppurativa with and without draining tunnels: a real-world study characterizing differences in treatment and disease burden","volume":"39","author":"Ingram","year":"2025","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"10.1016\/j.jaad.2025.11.031_bib17","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1016\/j.jaci.2020.12.651","article-title":"Epithelialized tunnels are a source of inflammation in hidradenitis suppurativa","volume":"147","author":"Navrazhina","year":"2021","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.jaad.2025.11.031_bib18","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1159\/000529848","article-title":"Tunnels in hidradenitis suppurativa: active inflammatory entities with specific molecular and genetic profiles \u2013 a narrative review","volume":"239","author":"Krajewski","year":"2023","journal-title":"Dermatology"},{"issue":"5","key":"10.1016\/j.jaad.2025.11.031_bib19","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1111\/jdv.20472","article-title":"European S2k guidelines for hidradenitis suppurativa\/acne inversa part 2: treatment","volume":"39","author":"Zouboulis","year":"2025","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"10.1016\/j.jaad.2025.11.031_bib20","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/jdv.15233","article-title":"Hidradenitis suppurativa\/acne inversa: a practical framework for treatment optimization \u2013 systematic review and recommendations from the HS ALLIANCE working group","volume":"33","author":"Zouboulis","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2025.11.031_bib21","first-page":"1","article-title":"Efficacy and safety of biologics for hidradenitis suppurativa: a network meta-analysis of phase III trials","author":"Calabrese","year":"2025","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"10378","key":"10.1016\/j.jaad.2025.11.031_bib22","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S0140-6736(23)00022-3","article-title":"Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials","volume":"401","author":"Kimball","year":"2023","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.jaad.2025.11.031_bib23","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.3390\/ijms23073753","article-title":"New and emerging targeted therapies for hidradenitis suppurativa","volume":"23","author":"Karkota \u010cagalj","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jaad.2025.11.031_bib24","doi-asserted-by":"crossref","first-page":"135","DOI":"10.2147\/CCID.S391356","article-title":"Adalimumab, ustekinumab, and secukinumab in the management of hidradenitis suppurativa: a review of the real-life experience","volume":"16","author":"Martora","year":"2023","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2025.11.031_bib25","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1001\/archdermatol.2009.49","article-title":"Long-term successful adalimumab therapy in severe hidradenitis suppurativa","volume":"145","author":"Blanco","year":"2009","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2025.11.031_bib26","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.3389\/fimmu.2020.01894","article-title":"Bimekizumab, a novel humanized igg1 antibody that neutralizes both IL-17A and IL-17F","volume":"11","author":"Adams","year":"2020","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.jaad.2025.11.031_bib27","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1093\/bjd\/ljae442","article-title":"The roles of IL-17A and IL-17F in hidradenitis suppurativa pathogenesis: evidence from human in vitro preclinical experiments and clinical samples","volume":"192","author":"Rastrick","year":"2024","journal-title":"Br J Dermatol"},{"issue":"10370","key":"10.1016\/j.jaad.2025.11.031_bib28","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S0140-6736(22)02303-0","article-title":"Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-\u03b1 inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE)","volume":"401","author":"Merola","year":"2023","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.jaad.2025.11.031_bib29","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1093\/bjd\/ljaf032","article-title":"Bimekizumab efficacy and safety through 3 years in patients with moderate-to-severe plaque psoriasis: Long-term results from the BE RADIANT phase IIIb trial open-label extension period","volume":"193","author":"Warren","year":"2025","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2025.11.031_bib30","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1136\/ard-2022-223595","article-title":"Efficacy and safety of bimekizumab in axial spondyloarthritis: results of two parallel phase 3 randomised controlled trials","volume":"82","author":"van der Heijde","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.jaad.2025.11.031_bib31","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1007\/s13555-025-01465-4","article-title":"Bimekizumab impact on patient-reported outcomes in patients with moderate to severe hidradenitis suppurativa: pooled 48-week results from BE HEARD I&II","volume":"15","author":"Shi","year":"2025","journal-title":"Dermatol Ther"},{"issue":"10443","key":"10.1016\/j.jaad.2025.11.031_bib32","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1016\/S0140-6736(24)00101-6","article-title":"Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials","volume":"403","author":"Kimball","year":"2024","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.jaad.2025.11.031_bib36","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1007\/s13555-025-01346-w","article-title":"Hidradenitis suppurativa symptom daily diary (HSSDD) and questionnaire (HSSQ): psychometric validation and interpretation threshold derivation using phase 3 study data","volume":"15","author":"Ingram","year":"2025","journal-title":"Dermatol Ther"},{"issue":"3","key":"10.1016\/j.jaad.2025.11.031_bib37","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","article-title":"Dermatology life quality index (DLQI): a simple practical measure for routine clinical use","volume":"19","author":"Finlay","year":"1994","journal-title":"Clin Exp Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2025.11.031_bib38","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa1504370","article-title":"Two phase 3 trials of adalimumab for hidradenitis suppurativa","volume":"375","author":"Kimball","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2025.11.031_bib39","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2022.1028943","article-title":"Sex-disaggregated population analysis in patients with hidradenitis suppurativa","volume":"9","author":"Sabat","year":"2022","journal-title":"Front Med"},{"issue":"5-6","key":"10.1016\/j.jaad.2025.11.031_bib40","first-page":"713","article-title":"Factors associated with severe hidradenitis suppurativa, using hurley staging and metascore","volume":"240","author":"Daoud","year":"2024","journal-title":"Dermatology"},{"issue":"4","key":"10.1016\/j.jaad.2025.11.031_bib41","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1093\/bjd\/ljae469","article-title":"Long-term efficacy and safety of secukinumab in patients with moderate-to-severe hidradenitis suppurativa: week 104 results from the SUNSHINE and SUNRISE extension trial","volume":"192","author":"Kimball","year":"2025","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2025.11.031_bib42","doi-asserted-by":"crossref","first-page":"191","DOI":"10.2340\/00015555-2815","article-title":"Clinical characteristics of pruritus and pain in patients with hidradenitis suppurativa","volume":"98","author":"Matusiak","year":"2018","journal-title":"Acta Derm Venereol"},{"issue":"16","key":"10.1016\/j.jaad.2025.11.031_bib43","doi-asserted-by":"crossref","first-page":"3648","DOI":"10.3390\/jcm10163648","article-title":"Pain as defining feature of health status and prominent therapeutic target in patients with hidradenitis suppurativa","volume":"10","author":"Sampogna","year":"2021","journal-title":"J Clin Med"},{"issue":"1","key":"10.1016\/j.jaad.2025.11.031_bib44","article-title":"Pain in hidradenitis suppurativa: a cross-sectional study of 1,795 patients","volume":"101","author":"Krajewski","year":"2021","journal-title":"Acta Derm Venereol"},{"issue":"Suppl 1","key":"10.1016\/j.jaad.2025.11.031_bib45","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/exd.14123","article-title":"Endpoints of clinical trials for hidradenitis suppurativa: proceedings of a round-table session","volume":"29","author":"Zouboulis","year":"2020","journal-title":"Exp Dermatol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S019096222503230X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S019096222503230X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T05:37:20Z","timestamp":1771393040000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S019096222503230X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":42,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S019096222503230X"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2025.11.031","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bimekizumab demonstrated a favorable safety profile and high levels of efficacy with up to 2 years of treatment in patients with moderate to severe hidradenitis suppurativa: Pooled results from two phase 3 randomized, controlled trials and their open-label extension","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2025.11.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}